Das hier ist eine Zusammenfassung aus einem anderen Forum. Ich hab es gestern auch live gehört und kann da so bestätigen. Bin aber zu faul alles selber aufzuschreiben;-)
Webcast zum nachhören ist hier:
https://event.webcasts.com/viewer/...ei=1258497&tp_key=0a694e230b
$PTN AMAG Presentation as to VYLEESI:
AVAILABILITY
- National Launch is 2 weeks away.
- Vyleesi Now available through 2 speciality pharmacies.
COPAY:
No copay 1st RX. Subsequent copay maximum exposure $99
MARKETING/INTEREST:
- Unbranded digital campaign over past 2 weeks to raise awareness of HSDD = 500,000 visits to unbranded website, 100,000 women filled out symptom checker
- Now pivoting to branded campaign telling them to see own Dr. or tele Dr.
- 6 weeks ago sent 20 trained reps into the field - feedback was + by Dr.’s, nurses for a condition they see often
SIDE EFFECTS:
Nausea - simple tolerability issue in minority of patient, that goes away with time. Counseled Dr.’s on this issue, pens are packaged as 4 pack combo, nausea will decrease and/or go away by 2-3-4 pen of pack.
Reiterated 80% of patients in study wanted to continue drug after completion.
REVENUE:
Don’t expect Vyleesi to be a big contributer to their Revenue in 2019 or 2020. |
